BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrueBinding\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies TrueBinding\, Inc.'s drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06773962-1727@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20261128
DTEND;VALUE=DATE:20261129
SUMMARY:TB006: Phase 2 readout est. (NCT06773962)
DESCRIPTION:TB006\, phase 2\, Parkinson's Disease.\nStudy: A Phase 2a Multi
 center Clinical Trial of TB006 in Participants With Parkinson's Disease\nE
 stimated primary completion: 28 November 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tb006#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06773962
URL:https://assetmemo.bio/drug/tb006#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
